Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cerus: This Blood-Safety Underdog Should Be Earning More Respect

2026-08-18

Cerus Corporation 2026 Q2 - Results - Earnings Call Presentation

2026-08-08
2026-08-08. The following slide deck was published by Cerus Corporation in conjunction with their 2026 Q2 earnings call.

Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

2026-07-31
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.

Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript

2026-07-30
Cerus Corporation (CERS) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsTimothy Lee - Head of Investor RelationVivek Jayaraman - CEO,...

Cerus Q2 Earnings Call Highlights

2026-07-30
Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas. Product revenue totaled $57.4 million for the quarter ended June

Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year Guidance

2026-07-30
Cerus Corp Q2 revenue beat estimates but stock fell 10% after hours on weaker full-year product guidance, citing margin pressure and lower government revenue.

Cerus Corporation Announces Second Quarter 2026 Financial Results

2026-07-30
CONCORD, Calif., July 30, 2026--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update.

12 Health Care Stocks Moving In Thursday's After-Market Session

2026-07-30
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure (NASDAQ:QURE) shares

Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate

2026-07-30
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 66.67 percent increase over losses of $(0.03) per share from the same period last year. The company

Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est

2026-07-30
Cerus (NASDAQ:CERS) raises FY2026 sales outlook from $227.000 million-$231.000 million to $229.000 million-$231.000 million vs $245.200 million estimate.